In this issue:
Benefit-risk profile of lenalidomide in lower-risk MDS without del(5q) Lenalidomide + prednisone in low- and intermediate-1-risk, non-del(5q) MDS
Paediatric-inspired protocol for high-risk adolescents and young adults with ALL
Maintenance sorafenib after allogeneic SCT for FLT3-mutated AML
Nivolumab for newly diagnosed, advanced-stage classic Hodgkin’s lymphoma
Guadecitabine for intermediate- or high-risk MDS
Ascending-dose study with open-label extension of voxelotor for sickle cell disease
Thromboembolic/bleeding risks following haematological cancers
Effect of low-level BCR-ABL1 kinase domain mutations in CML
Post-transplant GVHD prophylaxis in mismatched unrelated donor SCT recipients
Dose-finding study of ruxolitinib for myelofibrosis with low platelet counts
Please login below to download this issue (PDF)